nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCG2—Cladribine—multiple sclerosis	0.0845	0.139	CbGbCtD
Dabrafenib—ABCG2—Mitoxantrone—multiple sclerosis	0.0616	0.102	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—multiple sclerosis	0.0555	0.0916	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—multiple sclerosis	0.0323	0.0534	CbGbCtD
Dabrafenib—ABCG2—Dexamethasone—multiple sclerosis	0.032	0.0527	CbGbCtD
Dabrafenib—ABCB1—Methylprednisolone—multiple sclerosis	0.0305	0.0503	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—multiple sclerosis	0.0298	0.0493	CbGbCtD
Dabrafenib—CYP3A4—Fingolimod—multiple sclerosis	0.0283	0.0468	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—multiple sclerosis	0.0257	0.0424	CbGbCtD
Dabrafenib—ABCB1—Mitoxantrone—multiple sclerosis	0.0222	0.0367	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—multiple sclerosis	0.0208	0.0343	CbGbCtD
Dabrafenib—ABCB1—Betamethasone—multiple sclerosis	0.0198	0.0327	CbGbCtD
Dabrafenib—ABCB1—Prednisolone—multiple sclerosis	0.0195	0.0323	CbGbCtD
Dabrafenib—ABCB1—Prednisone—multiple sclerosis	0.0185	0.0305	CbGbCtD
Dabrafenib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0183	0.0301	CbGbCtD
Dabrafenib—CYP2C8—Dexamethasone—multiple sclerosis	0.017	0.0281	CbGbCtD
Dabrafenib—CYP3A4—Triamcinolone—multiple sclerosis	0.0138	0.0228	CbGbCtD
Dabrafenib—CYP3A4—Mitoxantrone—multiple sclerosis	0.0133	0.022	CbGbCtD
Dabrafenib—CYP3A4—Betamethasone—multiple sclerosis	0.0119	0.0196	CbGbCtD
Dabrafenib—CYP3A4—Prednisolone—multiple sclerosis	0.0117	0.0193	CbGbCtD
Dabrafenib—ABCB1—Dexamethasone—multiple sclerosis	0.0115	0.019	CbGbCtD
Dabrafenib—CYP3A4—Prednisone—multiple sclerosis	0.0111	0.0183	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—multiple sclerosis	0.00926	0.0153	CbGbCtD
Dabrafenib—CYP3A4—Dexamethasone—multiple sclerosis	0.0069	0.0114	CbGbCtD
Dabrafenib—NEK11—medulla oblongata—multiple sclerosis	0.00415	0.0977	CbGeAlD
Dabrafenib—NEK11—cerebellum—multiple sclerosis	0.00293	0.0691	CbGeAlD
Dabrafenib—LIMK1—midbrain—multiple sclerosis	0.00271	0.0639	CbGeAlD
Dabrafenib—NEK11—brain—multiple sclerosis	0.00238	0.0561	CbGeAlD
Dabrafenib—LIMK1—cerebellum—multiple sclerosis	0.0021	0.0495	CbGeAlD
Dabrafenib—RAF1—brainstem—multiple sclerosis	0.00175	0.0413	CbGeAlD
Dabrafenib—LIMK1—brain—multiple sclerosis	0.0017	0.0402	CbGeAlD
Dabrafenib—BRAF—midbrain—multiple sclerosis	0.00168	0.0395	CbGeAlD
Dabrafenib—SIK1—medulla oblongata—multiple sclerosis	0.00153	0.0362	CbGeAlD
Dabrafenib—SIK1—spinal cord—multiple sclerosis	0.00137	0.0323	CbGeAlD
Dabrafenib—BRAF—cerebellum—multiple sclerosis	0.0013	0.0306	CbGeAlD
Dabrafenib—RAF1—medulla oblongata—multiple sclerosis	0.00122	0.0288	CbGeAlD
Dabrafenib—SIK1—nervous system—multiple sclerosis	0.00115	0.0272	CbGeAlD
Dabrafenib—RAF1—midbrain—multiple sclerosis	0.00112	0.0263	CbGeAlD
Dabrafenib—SIK1—central nervous system—multiple sclerosis	0.00111	0.0262	CbGeAlD
Dabrafenib—RAF1—spinal cord—multiple sclerosis	0.00109	0.0257	CbGeAlD
Dabrafenib—SIK1—cerebellum—multiple sclerosis	0.00109	0.0256	CbGeAlD
Dabrafenib—BRAF—brain—multiple sclerosis	0.00105	0.0248	CbGeAlD
Dabrafenib—RAF1—nervous system—multiple sclerosis	0.000918	0.0216	CbGeAlD
Dabrafenib—RAF1—central nervous system—multiple sclerosis	0.000884	0.0208	CbGeAlD
Dabrafenib—SIK1—brain—multiple sclerosis	0.000881	0.0208	CbGeAlD
Dabrafenib—RAF1—cerebellum—multiple sclerosis	0.000864	0.0204	CbGeAlD
Dabrafenib—RAF1—brain—multiple sclerosis	0.000701	0.0165	CbGeAlD
Dabrafenib—SLC22A6—brain—multiple sclerosis	0.000681	0.0161	CbGeAlD
Dabrafenib—SLC22A8—nervous system—multiple sclerosis	0.000534	0.0126	CbGeAlD
Dabrafenib—SLC22A8—central nervous system—multiple sclerosis	0.000514	0.0121	CbGeAlD
Dabrafenib—ABCG2—medulla oblongata—multiple sclerosis	0.000505	0.0119	CbGeAlD
Dabrafenib—ABCG2—midbrain—multiple sclerosis	0.000462	0.0109	CbGeAlD
Dabrafenib—ABCG2—spinal cord—multiple sclerosis	0.000451	0.0106	CbGeAlD
Dabrafenib—SLC22A8—brain—multiple sclerosis	0.000408	0.00961	CbGeAlD
Dabrafenib—ABCG2—cerebellum—multiple sclerosis	0.000357	0.00842	CbGeAlD
Dabrafenib—ABCB1—retina—multiple sclerosis	0.000345	0.00813	CbGeAlD
Dabrafenib—CYP2C8—brain—multiple sclerosis	0.000298	0.00703	CbGeAlD
Dabrafenib—ABCG2—brain—multiple sclerosis	0.00029	0.00684	CbGeAlD
Dabrafenib—CYP3A4—nervous system—multiple sclerosis	0.000264	0.00623	CbGeAlD
Dabrafenib—CYP3A4—central nervous system—multiple sclerosis	0.000255	0.006	CbGeAlD
Dabrafenib—ABCB1—medulla oblongata—multiple sclerosis	0.000249	0.00587	CbGeAlD
Dabrafenib—Haemorrhage—Dexamethasone—multiple sclerosis	0.000241	0.00118	CcSEcCtD
Dabrafenib—Haemorrhage—Betamethasone—multiple sclerosis	0.000241	0.00118	CcSEcCtD
Dabrafenib—Angiopathy—Methylprednisolone—multiple sclerosis	0.000241	0.00118	CcSEcCtD
Dabrafenib—Rash—Cladribine—multiple sclerosis	0.00024	0.00118	CcSEcCtD
Dabrafenib—Dermatitis—Cladribine—multiple sclerosis	0.00024	0.00118	CcSEcCtD
Dabrafenib—Immune system disorder—Methylprednisolone—multiple sclerosis	0.00024	0.00118	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000239	0.00117	CcSEcCtD
Dabrafenib—Headache—Cladribine—multiple sclerosis	0.000239	0.00117	CcSEcCtD
Dabrafenib—Arrhythmia—Triamcinolone—multiple sclerosis	0.000238	0.00117	CcSEcCtD
Dabrafenib—Vision blurred—Prednisolone—multiple sclerosis	0.000237	0.00116	CcSEcCtD
Dabrafenib—Arrhythmia—Methylprednisolone—multiple sclerosis	0.000237	0.00116	CcSEcCtD
Dabrafenib—Hyperglycaemia—Prednisone—multiple sclerosis	0.000237	0.00116	CcSEcCtD
Dabrafenib—Hypotension—Mitoxantrone—multiple sclerosis	0.000234	0.00115	CcSEcCtD
Dabrafenib—Mental disorder—Methylprednisolone—multiple sclerosis	0.000233	0.00114	CcSEcCtD
Dabrafenib—Erythema—Triamcinolone—multiple sclerosis	0.000232	0.00114	CcSEcCtD
Dabrafenib—Malnutrition—Methylprednisolone—multiple sclerosis	0.000231	0.00113	CcSEcCtD
Dabrafenib—Erythema—Methylprednisolone—multiple sclerosis	0.000231	0.00113	CcSEcCtD
Dabrafenib—Hypersensitivity—Azathioprine—multiple sclerosis	0.000228	0.00112	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000228	0.00112	CcSEcCtD
Dabrafenib—ABCB1—midbrain—multiple sclerosis	0.000228	0.00537	CbGeAlD
Dabrafenib—Nausea—Cladribine—multiple sclerosis	0.000226	0.00111	CcSEcCtD
Dabrafenib—Eye disorder—Betamethasone—multiple sclerosis	0.000226	0.00111	CcSEcCtD
Dabrafenib—Eye disorder—Dexamethasone—multiple sclerosis	0.000226	0.00111	CcSEcCtD
Dabrafenib—Back pain—Triamcinolone—multiple sclerosis	0.000224	0.0011	CcSEcCtD
Dabrafenib—ABCB1—spinal cord—multiple sclerosis	0.000222	0.00524	CbGeAlD
Dabrafenib—Angiopathy—Dexamethasone—multiple sclerosis	0.000219	0.00107	CcSEcCtD
Dabrafenib—Angiopathy—Betamethasone—multiple sclerosis	0.000219	0.00107	CcSEcCtD
Dabrafenib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000218	0.00107	CcSEcCtD
Dabrafenib—Hypertension—Prednisolone—multiple sclerosis	0.000217	0.00107	CcSEcCtD
Dabrafenib—Fatigue—Mitoxantrone—multiple sclerosis	0.000216	0.00106	CcSEcCtD
Dabrafenib—Arrhythmia—Betamethasone—multiple sclerosis	0.000216	0.00106	CcSEcCtD
Dabrafenib—Arrhythmia—Dexamethasone—multiple sclerosis	0.000216	0.00106	CcSEcCtD
Dabrafenib—Pancreatitis—Methotrexate—multiple sclerosis	0.000215	0.00106	CcSEcCtD
Dabrafenib—Constipation—Mitoxantrone—multiple sclerosis	0.000214	0.00105	CcSEcCtD
Dabrafenib—Alopecia—Dexamethasone—multiple sclerosis	0.000213	0.00105	CcSEcCtD
Dabrafenib—Alopecia—Betamethasone—multiple sclerosis	0.000213	0.00105	CcSEcCtD
Dabrafenib—Diarrhoea—Azathioprine—multiple sclerosis	0.000212	0.00104	CcSEcCtD
Dabrafenib—Haemoglobin—Prednisone—multiple sclerosis	0.000211	0.00104	CcSEcCtD
Dabrafenib—Abdominal discomfort—Methotrexate—multiple sclerosis	0.00021	0.00103	CcSEcCtD
Dabrafenib—Haemorrhage—Prednisone—multiple sclerosis	0.00021	0.00103	CcSEcCtD
Dabrafenib—Erythema—Betamethasone—multiple sclerosis	0.00021	0.00103	CcSEcCtD
Dabrafenib—Erythema—Dexamethasone—multiple sclerosis	0.00021	0.00103	CcSEcCtD
Dabrafenib—Connective tissue disorder—Prednisone—multiple sclerosis	0.000207	0.00101	CcSEcCtD
Dabrafenib—Oedema—Prednisolone—multiple sclerosis	0.000205	0.00101	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—multiple sclerosis	0.000205	0.00101	CcSEcCtD
Dabrafenib—Dizziness—Azathioprine—multiple sclerosis	0.000205	0.00101	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000205	0.001	CcSEcCtD
Dabrafenib—Cough—Triamcinolone—multiple sclerosis	0.000202	0.000991	CcSEcCtD
Dabrafenib—Hypertension—Triamcinolone—multiple sclerosis	0.0002	0.000981	CcSEcCtD
Dabrafenib—Hypertension—Methylprednisolone—multiple sclerosis	0.000199	0.000979	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000199	0.000975	CcSEcCtD
Dabrafenib—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000198	0.000972	CcSEcCtD
Dabrafenib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000198	0.000972	CcSEcCtD
Dabrafenib—Myalgia—Triamcinolone—multiple sclerosis	0.000197	0.000967	CcSEcCtD
Dabrafenib—Vomiting—Azathioprine—multiple sclerosis	0.000197	0.000967	CcSEcCtD
Dabrafenib—Arthralgia—Methylprednisolone—multiple sclerosis	0.000197	0.000965	CcSEcCtD
Dabrafenib—Myalgia—Methylprednisolone—multiple sclerosis	0.000197	0.000965	CcSEcCtD
Dabrafenib—Eye disorder—Prednisone—multiple sclerosis	0.000196	0.000964	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—multiple sclerosis	0.000196	0.00096	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—multiple sclerosis	0.000196	0.00096	CcSEcCtD
Dabrafenib—Rash—Azathioprine—multiple sclerosis	0.000195	0.000959	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000195	0.000958	CcSEcCtD
Dabrafenib—Dermatitis—Azathioprine—multiple sclerosis	0.000195	0.000958	CcSEcCtD
Dabrafenib—Headache—Azathioprine—multiple sclerosis	0.000194	0.000952	CcSEcCtD
Dabrafenib—Dry mouth—Triamcinolone—multiple sclerosis	0.000193	0.000946	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—multiple sclerosis	0.000192	0.000944	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—multiple sclerosis	0.000191	0.000936	CcSEcCtD
Dabrafenib—Angiopathy—Prednisone—multiple sclerosis	0.000191	0.000936	CcSEcCtD
Dabrafenib—Immune system disorder—Prednisone—multiple sclerosis	0.00019	0.000932	CcSEcCtD
Dabrafenib—Oedema—Triamcinolone—multiple sclerosis	0.000189	0.000927	CcSEcCtD
Dabrafenib—Arrhythmia—Prednisone—multiple sclerosis	0.000188	0.000921	CcSEcCtD
Dabrafenib—Infection—Triamcinolone—multiple sclerosis	0.000188	0.000921	CcSEcCtD
Dabrafenib—Infection—Methylprednisolone—multiple sclerosis	0.000187	0.000919	CcSEcCtD
Dabrafenib—ABCB1—nervous system—multiple sclerosis	0.000187	0.00441	CbGeAlD
Dabrafenib—Haematuria—Methotrexate—multiple sclerosis	0.000187	0.000915	CcSEcCtD
Dabrafenib—Insomnia—Prednisolone—multiple sclerosis	0.000186	0.000912	CcSEcCtD
Dabrafenib—Alopecia—Prednisone—multiple sclerosis	0.000186	0.000911	CcSEcCtD
Dabrafenib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000185	0.000907	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—multiple sclerosis	0.000185	0.000906	CcSEcCtD
Dabrafenib—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000185	0.000905	CcSEcCtD
Dabrafenib—Mental disorder—Prednisone—multiple sclerosis	0.000184	0.000904	CcSEcCtD
Dabrafenib—Nausea—Azathioprine—multiple sclerosis	0.000184	0.000903	CcSEcCtD
Dabrafenib—Skin disorder—Methylprednisolone—multiple sclerosis	0.000183	0.000899	CcSEcCtD
Dabrafenib—Malnutrition—Prednisone—multiple sclerosis	0.000183	0.000898	CcSEcCtD
Dabrafenib—Erythema—Prednisone—multiple sclerosis	0.000183	0.000898	CcSEcCtD
Dabrafenib—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000183	0.000896	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000182	0.000894	CcSEcCtD
Dabrafenib—Hypertension—Dexamethasone—multiple sclerosis	0.000181	0.00089	CcSEcCtD
Dabrafenib—Hypertension—Betamethasone—multiple sclerosis	0.000181	0.00089	CcSEcCtD
Dabrafenib—ABCB1—central nervous system—multiple sclerosis	0.00018	0.00425	CbGeAlD
Dabrafenib—Asthenia—Mitoxantrone—multiple sclerosis	0.00018	0.000882	CcSEcCtD
Dabrafenib—Myalgia—Dexamethasone—multiple sclerosis	0.000179	0.000878	CcSEcCtD
Dabrafenib—Myalgia—Betamethasone—multiple sclerosis	0.000179	0.000878	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—multiple sclerosis	0.000177	0.000866	CcSEcCtD
Dabrafenib—Hypotension—Methylprednisolone—multiple sclerosis	0.000176	0.000865	CcSEcCtD
Dabrafenib—ABCB1—cerebellum—multiple sclerosis	0.000176	0.00415	CbGeAlD
Dabrafenib—Haemorrhage—Methotrexate—multiple sclerosis	0.000176	0.000862	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000173	0.000851	CcSEcCtD
Dabrafenib—Vision blurred—Prednisone—multiple sclerosis	0.000172	0.000846	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—multiple sclerosis	0.000172	0.000845	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000172	0.000845	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000172	0.000843	CcSEcCtD
Dabrafenib—Oedema—Betamethasone—multiple sclerosis	0.000171	0.000841	CcSEcCtD
Dabrafenib—Oedema—Dexamethasone—multiple sclerosis	0.000171	0.000841	CcSEcCtD
Dabrafenib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000171	0.000841	CcSEcCtD
Dabrafenib—Insomnia—Triamcinolone—multiple sclerosis	0.000171	0.000839	CcSEcCtD
Dabrafenib—Insomnia—Methylprednisolone—multiple sclerosis	0.000171	0.000837	CcSEcCtD
Dabrafenib—Infection—Betamethasone—multiple sclerosis	0.00017	0.000836	CcSEcCtD
Dabrafenib—Infection—Dexamethasone—multiple sclerosis	0.00017	0.000836	CcSEcCtD
Dabrafenib—Anaemia—Prednisone—multiple sclerosis	0.000169	0.00083	CcSEcCtD
Dabrafenib—Nervous system disorder—Betamethasone—multiple sclerosis	0.000168	0.000825	CcSEcCtD
Dabrafenib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000168	0.000825	CcSEcCtD
Dabrafenib—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000168	0.000824	CcSEcCtD
Dabrafenib—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000168	0.000824	CcSEcCtD
Dabrafenib—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000166	0.000813	CcSEcCtD
Dabrafenib—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000166	0.000813	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—multiple sclerosis	0.000164	0.000805	CcSEcCtD
Dabrafenib—Fatigue—Triamcinolone—multiple sclerosis	0.000163	0.000799	CcSEcCtD
Dabrafenib—Fatigue—Methylprednisolone—multiple sclerosis	0.000163	0.000798	CcSEcCtD
Dabrafenib—Hypotension—Dexamethasone—multiple sclerosis	0.00016	0.000786	CcSEcCtD
Dabrafenib—Hypotension—Betamethasone—multiple sclerosis	0.00016	0.000786	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—multiple sclerosis	0.000159	0.000782	CcSEcCtD
Dabrafenib—Vomiting—Mitoxantrone—multiple sclerosis	0.000159	0.000781	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—multiple sclerosis	0.000159	0.000779	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000158	0.000777	CcSEcCtD
Dabrafenib—Hypertension—Prednisone—multiple sclerosis	0.000158	0.000775	CcSEcCtD
Dabrafenib—Rash—Mitoxantrone—multiple sclerosis	0.000158	0.000775	CcSEcCtD
Dabrafenib—Dermatitis—Mitoxantrone—multiple sclerosis	0.000158	0.000774	CcSEcCtD
Dabrafenib—Chills—Methotrexate—multiple sclerosis	0.000158	0.000773	CcSEcCtD
Dabrafenib—Headache—Mitoxantrone—multiple sclerosis	0.000157	0.00077	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000156	0.000767	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000156	0.000767	CcSEcCtD
Dabrafenib—Arthralgia—Prednisone—multiple sclerosis	0.000156	0.000764	CcSEcCtD
Dabrafenib—Myalgia—Prednisone—multiple sclerosis	0.000156	0.000764	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—multiple sclerosis	0.000155	0.000762	CcSEcCtD
Dabrafenib—Insomnia—Dexamethasone—multiple sclerosis	0.000155	0.000761	CcSEcCtD
Dabrafenib—Insomnia—Betamethasone—multiple sclerosis	0.000155	0.000761	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000155	0.000759	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000154	0.000757	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—multiple sclerosis	0.000154	0.000755	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—multiple sclerosis	0.000153	0.00075	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—multiple sclerosis	0.000153	0.00075	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisolone—multiple sclerosis	0.000151	0.000743	CcSEcCtD
Dabrafenib—Body temperature increased—Triamcinolone—multiple sclerosis	0.000149	0.000733	CcSEcCtD
Dabrafenib—Oedema—Prednisone—multiple sclerosis	0.000149	0.000733	CcSEcCtD
Dabrafenib—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000149	0.000731	CcSEcCtD
Dabrafenib—Decreased appetite—Betamethasone—multiple sclerosis	0.000149	0.000731	CcSEcCtD
Dabrafenib—Decreased appetite—Dexamethasone—multiple sclerosis	0.000149	0.000731	CcSEcCtD
Dabrafenib—Nausea—Mitoxantrone—multiple sclerosis	0.000149	0.00073	CcSEcCtD
Dabrafenib—Infection—Prednisone—multiple sclerosis	0.000148	0.000728	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000148	0.000726	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000148	0.000726	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—multiple sclerosis	0.000148	0.000726	CcSEcCtD
Dabrafenib—Fatigue—Betamethasone—multiple sclerosis	0.000148	0.000725	CcSEcCtD
Dabrafenib—Fatigue—Dexamethasone—multiple sclerosis	0.000148	0.000725	CcSEcCtD
Dabrafenib—Nervous system disorder—Prednisone—multiple sclerosis	0.000146	0.000719	CcSEcCtD
Dabrafenib—Skin disorder—Prednisone—multiple sclerosis	0.000145	0.000712	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisone—multiple sclerosis	0.000144	0.000708	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—multiple sclerosis	0.000144	0.000707	CcSEcCtD
Dabrafenib—ABCB1—brain—multiple sclerosis	0.000143	0.00337	CbGeAlD
Dabrafenib—Anaemia—Methotrexate—multiple sclerosis	0.000141	0.000693	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.00014	0.000688	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.00014	0.000688	CcSEcCtD
Dabrafenib—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000139	0.000683	CcSEcCtD
Dabrafenib—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000139	0.000682	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—multiple sclerosis	0.000137	0.000672	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000136	0.000668	CcSEcCtD
Dabrafenib—Dizziness—Prednisolone—multiple sclerosis	0.000136	0.000667	CcSEcCtD
Dabrafenib—Asthenia—Triamcinolone—multiple sclerosis	0.000136	0.000665	CcSEcCtD
Dabrafenib—Abdominal pain—Dexamethasone—multiple sclerosis	0.000136	0.000665	CcSEcCtD
Dabrafenib—Body temperature increased—Dexamethasone—multiple sclerosis	0.000136	0.000665	CcSEcCtD
Dabrafenib—Abdominal pain—Betamethasone—multiple sclerosis	0.000136	0.000665	CcSEcCtD
Dabrafenib—Body temperature increased—Betamethasone—multiple sclerosis	0.000136	0.000665	CcSEcCtD
Dabrafenib—Asthenia—Methylprednisolone—multiple sclerosis	0.000135	0.000664	CcSEcCtD
Dabrafenib—Insomnia—Prednisone—multiple sclerosis	0.000135	0.000663	CcSEcCtD
Dabrafenib—Pruritus—Triamcinolone—multiple sclerosis	0.000134	0.000656	CcSEcCtD
Dabrafenib—Cough—Methotrexate—multiple sclerosis	0.000133	0.000655	CcSEcCtD
Dabrafenib—Pruritus—Methylprednisolone—multiple sclerosis	0.000133	0.000655	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—multiple sclerosis	0.00013	0.000639	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—multiple sclerosis	0.00013	0.000639	CcSEcCtD
Dabrafenib—Decreased appetite—Prednisone—multiple sclerosis	0.00013	0.000637	CcSEcCtD
Dabrafenib—Rash—Prednisolone—multiple sclerosis	0.00013	0.000636	CcSEcCtD
Dabrafenib—Dermatitis—Prednisolone—multiple sclerosis	0.000129	0.000635	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000129	0.000634	CcSEcCtD
Dabrafenib—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000129	0.000633	CcSEcCtD
Dabrafenib—Fatigue—Prednisone—multiple sclerosis	0.000129	0.000632	CcSEcCtD
Dabrafenib—Headache—Prednisolone—multiple sclerosis	0.000129	0.000632	CcSEcCtD
Dabrafenib—Constipation—Prednisone—multiple sclerosis	0.000128	0.000627	CcSEcCtD
Dabrafenib—Dizziness—Triamcinolone—multiple sclerosis	0.000125	0.000613	CcSEcCtD
Dabrafenib—Dizziness—Methylprednisolone—multiple sclerosis	0.000125	0.000612	CcSEcCtD
Dabrafenib—Infection—Methotrexate—multiple sclerosis	0.000124	0.000608	CcSEcCtD
Dabrafenib—Asthenia—Betamethasone—multiple sclerosis	0.000123	0.000604	CcSEcCtD
Dabrafenib—Asthenia—Dexamethasone—multiple sclerosis	0.000123	0.000604	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—multiple sclerosis	0.000122	0.000601	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000122	0.0006	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000122	0.000599	CcSEcCtD
Dabrafenib—Nausea—Prednisolone—multiple sclerosis	0.000122	0.000599	CcSEcCtD
Dabrafenib—Pruritus—Dexamethasone—multiple sclerosis	0.000121	0.000595	CcSEcCtD
Dabrafenib—Pruritus—Betamethasone—multiple sclerosis	0.000121	0.000595	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—multiple sclerosis	0.000121	0.000595	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000121	0.000592	CcSEcCtD
Dabrafenib—Vomiting—Triamcinolone—multiple sclerosis	0.00012	0.00059	CcSEcCtD
Dabrafenib—Vomiting—Methylprednisolone—multiple sclerosis	0.00012	0.000588	CcSEcCtD
Dabrafenib—Rash—Triamcinolone—multiple sclerosis	0.000119	0.000585	CcSEcCtD
Dabrafenib—Dermatitis—Triamcinolone—multiple sclerosis	0.000119	0.000584	CcSEcCtD
Dabrafenib—Rash—Methylprednisolone—multiple sclerosis	0.000119	0.000583	CcSEcCtD
Dabrafenib—Dermatitis—Methylprednisolone—multiple sclerosis	0.000119	0.000583	CcSEcCtD
Dabrafenib—Headache—Triamcinolone—multiple sclerosis	0.000118	0.000581	CcSEcCtD
Dabrafenib—Headache—Methylprednisolone—multiple sclerosis	0.000118	0.00058	CcSEcCtD
Dabrafenib—Body temperature increased—Prednisone—multiple sclerosis	0.000118	0.000579	CcSEcCtD
Dabrafenib—Abdominal pain—Prednisone—multiple sclerosis	0.000118	0.000579	CcSEcCtD
Dabrafenib—Diarrhoea—Dexamethasone—multiple sclerosis	0.000117	0.000576	CcSEcCtD
Dabrafenib—Diarrhoea—Betamethasone—multiple sclerosis	0.000117	0.000576	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—multiple sclerosis	0.000117	0.000572	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000114	0.000558	CcSEcCtD
Dabrafenib—Dizziness—Betamethasone—multiple sclerosis	0.000113	0.000556	CcSEcCtD
Dabrafenib—Dizziness—Dexamethasone—multiple sclerosis	0.000113	0.000556	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—multiple sclerosis	0.000113	0.000554	CcSEcCtD
Dabrafenib—Nausea—Triamcinolone—multiple sclerosis	0.000112	0.000551	CcSEcCtD
Dabrafenib—Nausea—Methylprednisolone—multiple sclerosis	0.000112	0.00055	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisone—multiple sclerosis	0.00011	0.00054	CcSEcCtD
Dabrafenib—Vomiting—Betamethasone—multiple sclerosis	0.000109	0.000535	CcSEcCtD
Dabrafenib—Vomiting—Dexamethasone—multiple sclerosis	0.000109	0.000535	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—multiple sclerosis	0.000108	0.000532	CcSEcCtD
Dabrafenib—Rash—Dexamethasone—multiple sclerosis	0.000108	0.00053	CcSEcCtD
Dabrafenib—Rash—Betamethasone—multiple sclerosis	0.000108	0.00053	CcSEcCtD
Dabrafenib—Dermatitis—Betamethasone—multiple sclerosis	0.000108	0.00053	CcSEcCtD
Dabrafenib—Dermatitis—Dexamethasone—multiple sclerosis	0.000108	0.00053	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000108	0.000529	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—multiple sclerosis	0.000108	0.000528	CcSEcCtD
Dabrafenib—Headache—Dexamethasone—multiple sclerosis	0.000107	0.000527	CcSEcCtD
Dabrafenib—Headache—Betamethasone—multiple sclerosis	0.000107	0.000527	CcSEcCtD
Dabrafenib—Asthenia—Prednisone—multiple sclerosis	0.000107	0.000526	CcSEcCtD
Dabrafenib—Pruritus—Prednisone—multiple sclerosis	0.000106	0.000518	CcSEcCtD
Dabrafenib—Diarrhoea—Prednisone—multiple sclerosis	0.000102	0.000501	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000102	0.000501	CcSEcCtD
Dabrafenib—Nausea—Dexamethasone—multiple sclerosis	0.000102	0.0005	CcSEcCtD
Dabrafenib—Nausea—Betamethasone—multiple sclerosis	0.000102	0.0005	CcSEcCtD
Dabrafenib—Dizziness—Prednisone—multiple sclerosis	9.87e-05	0.000485	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—multiple sclerosis	9.87e-05	0.000484	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—multiple sclerosis	9.87e-05	0.000484	CcSEcCtD
Dabrafenib—Vomiting—Prednisone—multiple sclerosis	9.49e-05	0.000466	CcSEcCtD
Dabrafenib—Rash—Prednisone—multiple sclerosis	9.42e-05	0.000462	CcSEcCtD
Dabrafenib—Dermatitis—Prednisone—multiple sclerosis	9.41e-05	0.000462	CcSEcCtD
Dabrafenib—Headache—Prednisone—multiple sclerosis	9.35e-05	0.000459	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—multiple sclerosis	9.19e-05	0.000451	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—multiple sclerosis	8.95e-05	0.000439	CcSEcCtD
Dabrafenib—Nausea—Prednisone—multiple sclerosis	8.87e-05	0.000435	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—multiple sclerosis	8.83e-05	0.000433	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—multiple sclerosis	8.54e-05	0.000419	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—multiple sclerosis	8.25e-05	0.000405	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—multiple sclerosis	7.93e-05	0.000389	CcSEcCtD
Dabrafenib—Rash—Methotrexate—multiple sclerosis	7.87e-05	0.000386	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—multiple sclerosis	7.86e-05	0.000386	CcSEcCtD
Dabrafenib—Headache—Methotrexate—multiple sclerosis	7.82e-05	0.000384	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—multiple sclerosis	7.41e-05	0.000364	CcSEcCtD
Dabrafenib—RAF1—Innate Immune System—HLA-B—multiple sclerosis	3.75e-05	0.000254	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD8A—multiple sclerosis	3.75e-05	0.000253	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—IL6—multiple sclerosis	3.74e-05	0.000253	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SRM—multiple sclerosis	3.74e-05	0.000252	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RGS1—multiple sclerosis	3.73e-05	0.000252	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	3.72e-05	0.000251	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—RRM1—multiple sclerosis	3.69e-05	0.000249	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL1B—multiple sclerosis	3.69e-05	0.000249	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	3.68e-05	0.000249	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL2—multiple sclerosis	3.68e-05	0.000248	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TNFAIP3—multiple sclerosis	3.65e-05	0.000247	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	3.64e-05	0.000246	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCR3—multiple sclerosis	3.63e-05	0.000245	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.62e-05	0.000245	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.6e-05	0.000244	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-B—multiple sclerosis	3.6e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—MAPK1—multiple sclerosis	3.59e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—IL6—multiple sclerosis	3.58e-05	0.000242	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GPR65—multiple sclerosis	3.54e-05	0.000239	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCR2—multiple sclerosis	3.53e-05	0.000238	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—multiple sclerosis	3.52e-05	0.000238	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—multiple sclerosis	3.5e-05	0.000237	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL1B—multiple sclerosis	3.48e-05	0.000235	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—multiple sclerosis	3.47e-05	0.000235	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	3.47e-05	0.000235	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL2—multiple sclerosis	3.47e-05	0.000235	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	3.46e-05	0.000234	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.43e-05	0.000232	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—BCHE—multiple sclerosis	3.41e-05	0.00023	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	3.4e-05	0.00023	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—multiple sclerosis	3.36e-05	0.000227	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—multiple sclerosis	3.35e-05	0.000226	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-A—multiple sclerosis	3.34e-05	0.000226	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL3—multiple sclerosis	3.33e-05	0.000225	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—multiple sclerosis	3.33e-05	0.000225	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—multiple sclerosis	3.31e-05	0.000224	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD28—multiple sclerosis	3.28e-05	0.000222	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CNR1—multiple sclerosis	3.26e-05	0.00022	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR1—multiple sclerosis	3.24e-05	0.000219	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL13—multiple sclerosis	3.24e-05	0.000219	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CCR2—multiple sclerosis	3.22e-05	0.000218	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTPRC—multiple sclerosis	3.22e-05	0.000218	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTGER4—multiple sclerosis	3.21e-05	0.000217	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.2e-05	0.000216	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TLR4—multiple sclerosis	3.18e-05	0.000215	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PGR—multiple sclerosis	3.16e-05	0.000213	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD86—multiple sclerosis	3.13e-05	0.000211	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—multiple sclerosis	3.12e-05	0.000211	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—multiple sclerosis	3.12e-05	0.000211	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	3.12e-05	0.000211	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DPB1—multiple sclerosis	3.12e-05	0.000211	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCR3—multiple sclerosis	3.1e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP9—multiple sclerosis	3.1e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—STAT3—multiple sclerosis	3.09e-05	0.000209	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.09e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—multiple sclerosis	3.09e-05	0.000209	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—multiple sclerosis	3.07e-05	0.000207	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CD28—multiple sclerosis	3.07e-05	0.000207	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—multiple sclerosis	3.06e-05	0.000207	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-DRB1—multiple sclerosis	3.05e-05	0.000206	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—multiple sclerosis	3.05e-05	0.000206	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—STAT3—multiple sclerosis	3.04e-05	0.000206	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.03e-05	0.000205	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD28—multiple sclerosis	3.03e-05	0.000205	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	3.02e-05	0.000204	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	3.02e-05	0.000204	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR2—multiple sclerosis	3.01e-05	0.000204	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40—multiple sclerosis	3e-05	0.000203	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ITGA4—multiple sclerosis	3e-05	0.000203	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNB1—multiple sclerosis	2.98e-05	0.000201	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTLA4—multiple sclerosis	2.95e-05	0.0002	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.95e-05	0.0002	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD80—multiple sclerosis	2.93e-05	0.000198	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL10—multiple sclerosis	2.93e-05	0.000198	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ICAM1—multiple sclerosis	2.93e-05	0.000198	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—STAT3—multiple sclerosis	2.92e-05	0.000197	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ALB—multiple sclerosis	2.82e-05	0.000191	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—MAPK1—multiple sclerosis	2.82e-05	0.000191	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD80—multiple sclerosis	2.82e-05	0.00019	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—MAPK1—multiple sclerosis	2.81e-05	0.00019	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TYK2—multiple sclerosis	2.8e-05	0.00019	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CNR1—multiple sclerosis	2.78e-05	0.000188	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CCR5—multiple sclerosis	2.77e-05	0.000187	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—MAPK1—multiple sclerosis	2.76e-05	0.000187	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPC5—multiple sclerosis	2.76e-05	0.000187	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	2.76e-05	0.000187	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HLA-A—multiple sclerosis	2.7e-05	0.000183	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	2.67e-05	0.00018	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.66e-05	0.000179	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—MAPK1—multiple sclerosis	2.65e-05	0.000179	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.63e-05	0.000178	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.63e-05	0.000178	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—VCAM1—multiple sclerosis	2.61e-05	0.000176	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DQA1—multiple sclerosis	2.6e-05	0.000176	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.53e-05	0.000171	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL5—multiple sclerosis	2.52e-05	0.000171	CbGpPWpGaD
Dabrafenib—BRAF—Disease—APOE—multiple sclerosis	2.52e-05	0.00017	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL10—multiple sclerosis	2.5e-05	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MAPK1—multiple sclerosis	2.5e-05	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TYK2—multiple sclerosis	2.48e-05	0.000167	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.44e-05	0.000165	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DQB1—multiple sclerosis	2.43e-05	0.000164	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.42e-05	0.000164	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPC5—multiple sclerosis	2.41e-05	0.000163	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD86—multiple sclerosis	2.34e-05	0.000158	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL3—multiple sclerosis	2.31e-05	0.000156	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.3e-05	0.000156	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SRM—multiple sclerosis	2.3e-05	0.000156	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40LG—multiple sclerosis	2.3e-05	0.000155	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—RRM1—multiple sclerosis	2.29e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2—multiple sclerosis	2.29e-05	0.000155	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—BCHE—multiple sclerosis	2.29e-05	0.000155	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD80—multiple sclerosis	2.28e-05	0.000154	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCR5—multiple sclerosis	2.27e-05	0.000154	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—multiple sclerosis	2.27e-05	0.000154	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2RA—multiple sclerosis	2.24e-05	0.000151	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—multiple sclerosis	2.24e-05	0.000151	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTGER4—multiple sclerosis	2.22e-05	0.00015	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP9—multiple sclerosis	2.21e-05	0.000149	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CD86—multiple sclerosis	2.19e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-B—multiple sclerosis	2.19e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PGR—multiple sclerosis	2.19e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD86—multiple sclerosis	2.16e-05	0.000146	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—multiple sclerosis	2.16e-05	0.000146	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL5—multiple sclerosis	2.16e-05	0.000146	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—multiple sclerosis	2.15e-05	0.000145	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCR3—multiple sclerosis	2.14e-05	0.000145	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.13e-05	0.000144	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.13e-05	0.000144	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—multiple sclerosis	2.12e-05	0.000144	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CD28—multiple sclerosis	2.12e-05	0.000143	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—BCHE—multiple sclerosis	2.12e-05	0.000143	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR2—multiple sclerosis	2.08e-05	0.000141	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—APOE—multiple sclerosis	2.05e-05	0.000138	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2RA—multiple sclerosis	2.05e-05	0.000138	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—multiple sclerosis	2.04e-05	0.000138	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-A—multiple sclerosis	2.02e-05	0.000137	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SPP1—multiple sclerosis	2e-05	0.000135	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—RRM1—multiple sclerosis	1.99e-05	0.000135	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—STAT3—multiple sclerosis	1.96e-05	0.000133	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR5—multiple sclerosis	1.94e-05	0.000131	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TYK2—multiple sclerosis	1.93e-05	0.00013	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CNR1—multiple sclerosis	1.92e-05	0.00013	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—multiple sclerosis	1.92e-05	0.00013	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CCR5—multiple sclerosis	1.92e-05	0.00013	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2RA—multiple sclerosis	1.91e-05	0.000129	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HLA-A—multiple sclerosis	1.87e-05	0.000126	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR4—multiple sclerosis	1.85e-05	0.000125	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DRB1—multiple sclerosis	1.85e-05	0.000125	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.84e-05	0.000124	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.84e-05	0.000124	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TGFB1—multiple sclerosis	1.82e-05	0.000123	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.8e-05	0.000122	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TGFB1—multiple sclerosis	1.79e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MAPK1—multiple sclerosis	1.79e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—POMC—multiple sclerosis	1.78e-05	0.00012	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.78e-05	0.00012	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ICAM1—multiple sclerosis	1.78e-05	0.00012	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APOE—multiple sclerosis	1.77e-05	0.000119	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—POMC—multiple sclerosis	1.76e-05	0.000119	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—MAPK1—multiple sclerosis	1.75e-05	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APOE—multiple sclerosis	1.75e-05	0.000118	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—multiple sclerosis	1.74e-05	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL2—multiple sclerosis	1.74e-05	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL10—multiple sclerosis	1.73e-05	0.000117	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.71e-05	0.000116	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD80—multiple sclerosis	1.71e-05	0.000115	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—multiple sclerosis	1.7e-05	0.000115	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.62e-05	0.00011	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.62e-05	0.00011	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ALB—multiple sclerosis	1.61e-05	0.000108	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CD80—multiple sclerosis	1.6e-05	0.000108	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TYK2—multiple sclerosis	1.58e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD80—multiple sclerosis	1.58e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MAPK1—multiple sclerosis	1.58e-05	0.000107	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.53e-05	0.000103	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—POMC—multiple sclerosis	1.52e-05	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CD86—multiple sclerosis	1.51e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL5—multiple sclerosis	1.49e-05	0.000101	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL2—multiple sclerosis	1.48e-05	0.0001	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.48e-05	0.0001	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TYK2—multiple sclerosis	1.44e-05	9.75e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.39e-05	9.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SPP1—multiple sclerosis	1.38e-05	9.33e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOE—multiple sclerosis	1.38e-05	9.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—multiple sclerosis	1.37e-05	9.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—multiple sclerosis	1.35e-05	9.13e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TYK2—multiple sclerosis	1.35e-05	9.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STAT3—multiple sclerosis	1.35e-05	9.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR5—multiple sclerosis	1.34e-05	9.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TYK2—multiple sclerosis	1.33e-05	9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2RA—multiple sclerosis	1.32e-05	8.95e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.32e-05	8.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—multiple sclerosis	1.31e-05	8.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—multiple sclerosis	1.3e-05	8.82e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOE—multiple sclerosis	1.27e-05	8.62e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—multiple sclerosis	1.25e-05	8.47e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—multiple sclerosis	1.25e-05	8.44e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.23e-05	8.31e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAPK1—multiple sclerosis	1.23e-05	8.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—multiple sclerosis	1.22e-05	8.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—multiple sclerosis	1.21e-05	8.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—multiple sclerosis	1.21e-05	8.14e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—multiple sclerosis	1.2e-05	8.14e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—multiple sclerosis	1.2e-05	8.11e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—POMC—multiple sclerosis	1.18e-05	7.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.15e-05	7.79e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—BCHE—multiple sclerosis	1.15e-05	7.74e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—multiple sclerosis	1.12e-05	7.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CD80—multiple sclerosis	1.11e-05	7.47e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—POMC—multiple sclerosis	1.1e-05	7.4e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—multiple sclerosis	1.08e-05	7.29e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—multiple sclerosis	1.06e-05	7.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—POMC—multiple sclerosis	1.05e-05	7.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—multiple sclerosis	1.03e-05	6.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—multiple sclerosis	1.01e-05	6.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK1—multiple sclerosis	1.01e-05	6.79e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—multiple sclerosis	9.99e-06	6.75e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—multiple sclerosis	9.44e-06	6.38e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—multiple sclerosis	9.42e-06	6.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TYK2—multiple sclerosis	9.33e-06	6.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—multiple sclerosis	9.33e-06	6.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK1—multiple sclerosis	9.18e-06	6.21e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—multiple sclerosis	8.77e-06	5.93e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—multiple sclerosis	8.75e-06	5.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—multiple sclerosis	8.67e-06	5.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—multiple sclerosis	8.65e-06	5.84e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK1—multiple sclerosis	8.58e-06	5.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK1—multiple sclerosis	8.48e-06	5.73e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—multiple sclerosis	7.91e-06	5.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—multiple sclerosis	7.76e-06	5.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—multiple sclerosis	7.72e-06	5.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—multiple sclerosis	7.35e-06	4.96e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BCHE—multiple sclerosis	7.06e-06	4.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—multiple sclerosis	7.06e-06	4.77e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—multiple sclerosis	6.89e-06	4.66e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—POMC—multiple sclerosis	6.8e-06	4.59e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—multiple sclerosis	6.59e-06	4.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—multiple sclerosis	6.53e-06	4.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—multiple sclerosis	6.52e-06	4.4e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—multiple sclerosis	6.2e-06	4.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—multiple sclerosis	6.07e-06	4.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—multiple sclerosis	6.05e-06	4.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK1—multiple sclerosis	5.94e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—POMC—multiple sclerosis	5.92e-06	4e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—multiple sclerosis	5.4e-06	3.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—multiple sclerosis	4.56e-06	3.08e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—multiple sclerosis	4.25e-06	2.87e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—POMC—multiple sclerosis	3.65e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—multiple sclerosis	3.33e-06	2.25e-05	CbGpPWpGaD
